Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Authors:
- 17 February 2025
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (S2) , 16-22
Abstract
Backbone therapy for acute myeloid leukemia for younger adults has for 50 years been based on a combination of cytarabine and anthracycline. Over the past 10 years the addition of several targeted agents has been found to improve the outcomes of subsets of AML with particular molecular changes. In this review we will examine the data generated to date on the addition of agents targeting CD33, FLT3, IDH, and BCL2 to standard high intensity therapies. We will also review the potential for future studies evaluating the application of highly active lower intensity therapies developed in older adults to patients considered “fit for high intensity induction.” Lastly, we review the data around the role of stem cell transplant in the modern targeted era.Keywords
This publication has 74 references indexed in Scilit:
- Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemiaAmerican Journal of Hematology, 2024
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐AAmerican Journal of Hematology, 2022
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2022
- Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblast Leukemia: A Systematic ReviewTransplantation and Cellular Therapy, 2020
- A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationTransplantation and Cellular Therapy, 2020
- Epidemiology of acute myeloid leukemia: Recent progress and enduring challengesBlood Reviews, 2019
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemiaCancer Cell, 2006